revealed stratifin as a biomarker for drug-induced ILD via diffuse alveolar damage, and testing stratifin in serum can distinguish diffuse alveolar damage from other histopathological patterns of ILD or other lung diseases.31 This evidence concerns the gene SFN and interstitial lung disease.